EP08.01-002 Real-World Survival Outcomes of Patients with High PD-L1 Advanced NSCLC Who Received Chemo-Immunotherapy vs Immunotherapy

Abstract

Randomised studies have demonstrated superior overall survival (OS) of pembrolizumab, both alone and in combination with chemotherapy over chemotherapy alone in patients with programmed cell death ligand 1 (PD-L1) ≥50% advanced non-small cell lung cancer (NSCLC). We reviewed the real-world outcomes of patients who received pembrolizumab-chemotherapy combination versus pembrolizumab alone.